[Skip To Content]
[Website of the National Cancer Institute's Technology Transfer Center. Partnering with Industry for Improved Public Health.]
  • Home
  • Collaborative Opportunities
  • Standard Forms and Agreements
  • Technology Transfer Training
  • Resources
  • Intellectual Property

Wip1 Peptide Inhibitors as Cancer Therapeutics

Background:
The National Cancer Institute's Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize Cyclic Phosphopeptide Inhibitors of Protein Phosphatase 2C Delta, Wip1.

Wip1 (PP2Cdelta or PPM1D) is a protein phosphatase that negatively regulates apoptosis by preventing p53-mediated cell-cycle arrest and apoptosis. Wip1 is overexpressed in several human cancers, including breast cancer, ovarian clear cell adenocarcinoma and neuroblastoma, suggesting it may play an important role in oncogenesis. Inhibiting Wip1 may be a necessary step for inducing apopotsis and prohibiting tumor growth, accentuating the need for Wip1-directed therapies.

Technology:
This technology involves the development of specific peptides that serve as Wip1 peptide inhibitors and can be used as anti-cancer agents, particularly as promoters of apoptosis. The inventors have modified the natural substrate of the Wip1 protein phosphatase in order to produce the inhibitors, allowing for specific and efficient inhibition of Wip1. The inhibitors may be combined with other pro-apoptosis therapeutics to improve patient survival, providing an advantage to previous pro-apoptosis approaches. Because these peptide inhibitors are the first specific Wip1 inhibitors, they represent the first opportunity to pursue this therapeutic strategy.

R&D Status:
Pre-clinical (discovery)

IP Status:
U.S. Provisional Application No. 60/850,218; Pending PCT Application PCT/US2006/022180.

Value Proposition:
Therapeutics to treat a variety of cancers, including breast cancer, ovarian, cancer, and neuroblastomas.

Contact Information:
John D. Hewes, Ph.D., NCI Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov

Reference:  #594 LW

Posted 12/17/2007

E-MAIL SERVICE

TTC maintains an e-mail service to notify you of new Collaborative Opportunities. If you would like to receive these emails, please sign up below. If you'd like to unsubscribe you can use this form as well.

Page Last Updated: 12-17-2008